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a b s t r a c t 
Background: Current algorithm for Congenital Chagas Disease (cCD) diagnosis is unsatisfactory due to low 
sensitivity of the parasitological methods. Moreover, loss to follow-up precludes final serodiagnosis after 
nine months of life in many cases. A duplex TaqMan qPCR kit for Trypanosoma cruzi DNA amplification 
was prospectively evaluated in umbilical cord (UCB) and peripheral venous blood (PVB) of infants born 
to CD mothers at endemic and non-endemic sites of Argentina. 
Methods: We enrolled and followed-up 370 infants; qPCR was compared to gold-standard cCD diagnosis 
following studies of diagnostic accuracy guidelines. 
Findings: Fourteen infants (3 ·78%) had cCD. The qPCR sensitivity and specificity were higher in PVB 
(72 ·73%, 99 ·15% respectively) than in UCB (66 ·67%, 96 ·3%). Positive and negative predictive values were 
80 and 98 ·73% and 50 and 98 ·11% for PVB and UCB, respectively. The Areas under the Curve (AUC) of 
ROC analysis for qPCR and micromethod (MM) were 0 ·81 and 0 ·67 in UCB and 0 ·86 and 0 ·68 in PVB, 
respectively. Parasitic loads ranged from 37 ·5 to 23,709 parasite equivalents/mL. Discrete typing Unit Tc 
V was identified in five cCD patients and in six other cCD cases no distinction among Tc II, Tc V or Tc VI 
was achieved. 
Interpretation: This first prospective field study demonstrated that qPCR was more sensitive than MM for 
early cCD detection and more accurate in PVB than in UCB. Its use, as an auxiliary diagnostic tool to MM 
will provide more accurate records on cCD incidence. 
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Research in context 
Evidence before this study 
Successful control of vectorial and transfusional transmis- 
sion has exposed public health importance of Congenital Cha- 
gas disease (cCD), which nowadays is the main route of Cha- 
gas disease (CD) urbanization in non-endemic areas. In 2010, 
the WHO recommended governments to launch systems of 
early detection of new infections and congenital infections in 
newborns. It was estimated that new cases of cCD in endemic 
regions represented 22% of all new cases of CD. Six years 
later, the Panamerican Health Organization incorporated cCD 
in the Elimination of mother-to-child transmission (EMTCT) 
-Plus initiative to boost control of vertical infections in the 
region, together with HIV, Syphilis and Hepatitis B. 
Current diagnosis of cCD is based on positive micro- 
scopic tests performed shortly after birth and/or by sero- 
logical reactivity after 9 months of age. However, this diag- 
nostic algorithm is unsatisfactory due to the low sensitivity 
and operator-dependence of parasitological methods and loss 
to follow-up once the neonate leaves maternity, a frequent 
event in rural endemic areas, where population is more vul- 
nerable. 
Polymerase chain reaction (PCR) methodology has been 
proposed as a higher sensitive and specific laboratory tool 
compared to current diagnostics algorithm for early diagnosis 
of cCD, but no prospective field evaluations have been done. 
Added value of this study 
This is the first prospective field evaluation of Real Time 
PCR (qPCR) accuracy for early diagnosis of cCD in endemic 
and non-endemic sites for CD, in comparison with current di- 
agnostics algorithm following Standards for Reporting of Di- 
agnostic Accuracy guidelines. The study compared the perfor- 
mance of a qPCR assay using as starting clinical material, um- 
bilical cord and peripheral blood samples of newborns and 
infants born to CD women. Furthermore, parasitic loads were 
estimated and discrete typing units of the infecting para- 
site populations were genotyped using molecular amplifica- 
tion strategies. The qPCR assay accuracy was higher in pe- 
ripheral venous blood than in umbilical cord blood samples 
and its clinical sensitivity was almost twice than that of the 
current parasitological method. 
Implications of all the available evidence 
The implementation of this qPCR assay will improve early 
detection of cases, provide more accurate records on the 
number of infants born to CD mothers in endemic and non- 
endemic countries and allow estimating the likely number of 
cases missed in places where only traditional parasitological 
procedures are still employed. 
Furthermore, early qPCR diagnosis will contribute to max- 
imize prompt treatment of infected neonates, with high im- 
pact in public health. 
. Introduction 
Successful control of vectorial and transfusional transmission 
as exposed public health importance of congenital Chagas disease 
cCD). ∗ Corresponding author. 
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2 Due to migrations from endemic areas to vector-free subur- 
an and urban centers, cCD is mainly accountable for Chagas dis- 
ase (CD) urbanization [1] . The parasite may be transmitted from 
other-to-child during pregnancy or at delivery and may infect 
wins and siblings in successive generations [ 2 , 3 ]. 
Current diagnosis of cCD is based on positive parasitological 
ests shortly after birth and/or serological reactivity after nine 
onths of age. Parasitological techniques detect motile parasites 
n umbilical cord blood (UCB) or peripheral venous blood (PVB), 
oncentrate parasites by centrifugation using capillary (microhe- 
atocrite) or microcentrifuge tubes (microMethod (MM)) followed 
y microscopic examination of the buffy coat. If the test is neg- 
tive at birth, it can be repeated at one month of age, when the 
eak of parasitemia is usually observed. These parasitological tests 
equire prompt processing of the sample to allow visualization of 
otile parasites, experienced laboratory operators and at least half 
n hour of microscopic observation per sample for adequate sensi- 
ivity. However, all these conditions are seldom achieved in public 
ealth laboratories. Other parasitological strategies, such as hemo- 
ulture, are not routinely used for diagnosis of cCD. The sensitivity 
f parasitological methods is disappointing, and in more than 50% 
f neonates, final diagnosis can only be done by means of serolog- 
cal analysis. A main concern is that 75-80% of infants do not go 
ack to the health centers for diagnosis confirmation, precluding 
heir opportunity to treatment, which is highly successful when 
mplemented during the first year of life [ 4 , 5 ]. 
Home-brewed and Real Time PCR (qPCR) studies have encour- 
ged the use of molecular diagnostics for early detection of cCD 
4–7] . The incorporation of nucleic acid amplification methods to 
he current diagnostics algorithm would allow early detection of a 
igher proportion of infected cases that are not detected by para- 
itological methods, preventing their loss to follow-up and allow- 
ng their prompt treatment. Indeed, the efficacy of treatment with 
ifurtimox or Benznidazole increases closer to birth with higher 
pportunity to demonstrate cure, while if left untreated the infec- 
ion progresses to chronic CD with a fall in the cure rate [8] . Access
o treatment before the first year of age has shown 99% of efficacy 
nd is the main strategy to interrupt congenital transmission to fu- 
ure generations. 
T. cruzi qPCR tests have recently become commercially avail- 
ble in Europe [9] . However, no evaluation of standardized qPCR 
its has been done so far in the context of prospective blind-based 
tudies [ 4–7 , 9 ]. Our central hypothesis proposes that a qPCR stan-
ardized method will depict better accuracy than that of current 
arasitological tests to detect cCD at birth and/or within the first 
onths of age in infants born to seropositive mothers. Our aim 
as to evaluate the sensitivity and specificity of a duplex Taq- 
an Real Time qPCR kit designed for qualitative detection of T. 
ruzi DNA in UCB and PVB samples. The performance of this in- 
ex test was compared to that of current parasitological diagno- 
is in prospective clinical samples from neonates born to infected 
others that attended public health centers in endemic and non- 
ndemic sites of Argentina. Furthermore, to characterize T. cruzi 
nfection in cCD infants, parasitic loads and discrete typing units 
DTUs) were determined directly from their qPCR positive blood 
amples [ 10 , 11 ]. 
. Methods 
.1. Study design 
This study followed the endorsements for “studies of diagnos- 
ic accuracy” (STARD). It aimed to estimate, on a blind basis, the 
ccuracy (sensitivity and specificity) of a qPCR prototype kit as in- 
ex test, using as gold standard the current diagnostics algorithm 















































































































or cCD: MM at birth and between four to eight weeks of age and
erological analysis after nine months of age [ 11 , 12 ]. 
The evaluation was performed at five public health care cen- 
ers (HC) in Argentina: the Instituto Nacional de Parasitología Dr. 
. Fatala Chabén - ANLIS Dr. C. G. Malbrán (INP), in Buenos Aires 
ity (HC1), and the remainder in endemic Provinces: Instituto de 
aternidad y Ginecología “Nuestra Señora de las Mercedes”, San 
iguel de Tucumán, Tucumán (HC2), Hospital “Dr. Julio C. Per- 
ando” in Resistencia, Chaco (HC3); Hospital Regional “Dr. Ramón 
arrillo”, Santiago del Estero city and Centro Integral de Salud La 
anda, Santiago del Estero (HC4 and HC5, respectively). The per- 
onnel involved in the field study together with the researchers 
esponsible for the project design, execution and analysis formed 
he Congenital Chagas Disease Study Group (Supplemental File). 
.2. Ethical statement 
Protocols were approved by the Bioethics committees of the 
articipant centers, after first approval of the Institutional review 
oard (IRB) at “Centro de Educación Médica e Investigaciones Clíni- 
as Norberto Quirno” (CEMIC), Buenos Aires. 
.3. Participants 
T. cruzi- infected women older than 18 years old diagnosed by 
outine serological analysis following the Guidelines of the Na- 
ional Ministry of Health [13] and residing within 50 km from the 
orresponding HC, were eligible for enrollment and invited to par- 
icipate. Those living outside the catchment area were excluded. 
other-newborns sample size was estimated using EpiData Soft- 
are version 3.1 ( http://www.epidata.dk ). Assuming an expected 
ensitivity of 90% for qPCR and 50% for MM and a 4% mean rate of
ertical transmission (5 ·55% in 2011; 5 ·08% in 2012; 3 ·08% in 2013)
14] ; at least 483 mothers were planned to be enrolled, expecting 
% of loss to follow-up. Eligible women signed a written informed 
onsent before enrollment. Only live births occurring between 8.00 
m to 8.00 pm were enrolled at endemic provinces. Health center 
, without a Maternity service, enrolled outpatients aged between 
ne and 22 weeks, weighing more than 3 kilograms. 
Clinical and socio demographic characteristics relevant to T. 
ruzi infection and potential risk factors for cCD transmission were 
ocumented: residence in rural area, presence of triatomine bugs 
nside patients’ houses, maternal HIV co-infection, mothers stating 
aving received trypanocidal treatment, previous gestations, older 
iblings infected by T. cruzi , vaginal delivery, breastfeeding at four 
o eight weeks visit and ten months visit, and cracked nipples with 
leeding. 
Complete cases were children from whom at least one early 
ample was collected for qPCR and MM analysis and a second one 
round ten months of age for serological analysis. 
.4. Sample collection for laboratory tests 
Five mL of UCB was drawn after birth, as reported [7] . The UCB
as collected in two tubes, one containing EDTA (4 mL) to perform 
he index test and the other one containing heparin (1 mL) to per- 
orm the reference test. Heparin-treated samples were stored for a 
aximum of 12 hours at 4 °C and prior to microscopic observation 
he tubes were stored 30 minutes at room temperature. 
Peripheral venous blood was obtained at birth if UCB was not 
vailable, or at four to 16 weeks of life in 1 ·5 mL EDTA-treated 
ubes for qPCR and 1 mL of heparinized-blood tubes for MM. Fi- 
ally, PVB was drawn at ten months of age in Vacutainer tubes 
or serological examination. An aliquot was centrifuged for serum 
ollection, kept in buffered glycerin and sent to INP laboratory for 3 erology analysis. A volume of 1 ·2 mL of EDTA-PVB was collected 
n 2 mL microtubes for genotyping of T. cruzi DTUs. 
All EDTA-blood samples were homogenized with a 
uanidinium-based stabilizing reagent (DNAgard, Biomatrica, 
SA) in the proportion 1:4 (vol: vol) of stabilizer: blood and 
tored at 4 °C for qPCR. 
At each period of sample collection, samples were codified and 
ept in a double-blind form for all participants in the study. 
.5. Index test 
A TaqMan based duplex qPCR assay targeting T. cruzi satel- 
ite DNA sequence and an internal amplification control (IAC) 
as developed and standardized. The satellite DNA based primers 
nd probe sequences are primer cruzi forward: 5‘GGGAGTCAGAGR- 
ACTCTC3‘, primer cruzi reverse: 5‘AATTCCTCCAAGMAGCGGATA3‘ 
nd cruzi probe: FAM-CACACACTGGACACCAAACAACCC-BHQ1. They 
ere designed after alignment of database T. cruzi satellite DNA 
equences (TriTrypDB, RRID:SCR_007043) to have a relatively well- 
onserved sequence recognized in all DTUs. The primers and probe 
equences for IAC were modified from those published by Duffy 
nd colleagues [10] . They are primer IAC forward: 5‘CGTCATG- 
AACAGCACGTAC3‘, primer IAC reverse: 5‘ACCAAGACGAAAGC- 
AAAACACC3‘ and IAC probe HEX-TGA C TGGATTTGGAGCAT C TGTTC- 
HQ1 (underlined Cs are locked nucleic acid residues). 
The assay has been developed into a commercial product man- 
factured by Wiener Laboratorios, S.A.I.C and released to the mar- 
et as “T. cruzi DNA test” for in-vitro diagnostics use (IVD), after 
pproval by the “Administración Nacional de Medicamentos, Al- 
mentos y Tecnología Médica”, ANMAT, Argentina, under the ID 
M 1102-173 (Supplemental Data). The index test was carried out 
t LaBMECh, INGEBI in collaboration with Wiener Laboratorios, 
.A.I.C., where the batch of the kit for the field study was pro- 
uced. Nucleic Acids were extracted from 250 μL of stabilized 
lood, adding 5 μL of linear IAC (40 pg/μL) prior extraction with 
he High Pure PCR Template Preparation kit (Roche Diagnostics, 
ermany) [10] . No more than 12 blood samples plus a negative 
ontrol (seronegative blood) were purified in the same experiment. 
he qPCR was performed in duplicates from each DNA extract. The 
it included Uracil DNA Glycosylase to avoid carry-over contami- 
ation from previously amplified products. The reaction contained 
 μL of DNA sample in a final volume of 20 μL. The qPCR plates
ere run in an ABI 7500 thermocycler (Applied Biosystems, Cali- 
ornia, USA). Cycling conditions were one cycle of 2 min at 50 °C, 
0 min at 95 °C and 45 cycles at 95 °C, 15 sec and 58 °C, 1 min. 
.6. External Quality assurance of qPCR performance 
An external quality assurance of qPCR performance was built- 
p at the Research & Development Department of INP to evalu- 
te the methodology implemented. Three proficiency testing pan- 
ls made of seronegative human blood samples spiked with 1 ·5 
P102 sample), 15 (P103 sample) and 150 (P104 sample) parasite 
quivalents/mL of T. cruzi (a Tc V strain isolated from a cCD case 
4] ) and a negative blood control without parasites (P101 sam- 
le) were evaluated in three laboratories using different thermo- 
yclers: ABI 7500 (Applied Biosystem, California, USA), Light Cy- 
ler 96 (Roche Diagnostic Rotkreuz, Switzerland), CFX96 Touch Real 
ime PCR Detection System (Bio Rad laboratories, California, USA). 
ach operator ran the assays from each panel in duplicates and 
n two consecutive days. The Cts were registered and qualitative 
esults were expressed as non-detectable or positive. The reports 
ere sent to the reference laboratory for statistical analysis. Intra- 
nd inter-laboratory qPCR results from the proficiency testing pan- 
ls were analyzed by SPSS Statistics software. The Cohen kappa co- 
fficient was used to analyze the closeness of the agreement and 









































































































he differences between qualitative qPCR results obtained from the 
amples tested at the three participating laboratories. The Analyse- 
t software for Microsoft Excel 5.30.2 Build 7069-17990 was used 
or this analysis. The performances of each participating Labora- 
ory were compared in terms of the Z score, in accordance with 
SO 13528:2015(E) [11] . The Z-score was negative or positive when 
ata points were below or above the mean, respectively. 
.7. Reference standards 
The MM was done in each HC on duplicates using 500μL of 
eparinized blood collected into Vacutainer tubes and loaded into 
mL microtubes, as reported [12] . Serological assays were per- 
ormed at ten to 12 months of age using Chagatest ELISA recom- 
inante v.3.0 and Chagatest HAI assays (Wiener Laboratories, Ar- 
entina) at the INP, using the cut-off values recommended by the 
anufacturers. Two positive serological tests were necessary for 
CD diagnosis; in case of discordance, an indirect immunofluores- 
ence (IFI) test was performed, following the recommendations of 
he manufacturer [15] . 
.8. Definition and rationale for test positivity 
.8.1. Index test 
Pre-analytical issues such as incorrect sample volume, coagu- 
ated sample, viscous sample hard to pipette, detected upon sam- 
le reception at LabMECh in INGEBI, determined that an UCB or 
VB sample had to be excluded for analysis of qPCR accuracy. An- 
lytical issues such as getting outlier (cycle threshold) Ct values of 
AC, which were estimated for each qPCR run using the Tukey ́s cri- 
eria (Ct > 75th percentile + 1.5 × interquartile distance of median 
t) [10] determined that the qPCR result was taken as not valid for 
nalysis of accuracy. 
A sample was defined as qPCR positive only if both DNA dupli- 
ates were qPCR positive with (quantification cycle) Cq values < 39, 
sing a threshold value of 0 ·04 (ABI 7500 thermocycler) and was 
eported as non-detectable when the Cq of both duplicates were 
39 or were non-detectable. Samples showing only one qPCR posi- 
ive replicate (Cq < 39) and the other one negative were considered 
s inconclusive and excluded for analysis of qPCR accuracy. 
.8.2. Reference tests 
After 15 minutes of microscopic observation (40x) of each MM 
uplicate, the motility of trypomastigotes was indicative of a pos- 
tive sample [12] . Serological positivity was determined according 
o the guidelines of the manufacturers for each test. 
Clinical information and reference standard results were not 
vailable to the performers/readers of the index test. The index test 
esults were not available to the health personnel responsible for 
he analyses of the reference tests. Only a positive MM or reactiv- 
ty of two serological tests confirmed cCD and were the criterions 
o derive the patient for treatment, as indicated by national guide- 
ines. 
.9. qPCR analysis of clinical samples 
Standard operative procedures for sample collection, conserva- 
ion, transportation, DNA extraction, qPCR amplification and inter- 
retation of qPCR results were redacted. Estimation of qPCR sen- 
itivity and specificity was done only in valid samples. Sensitivity 
as calculated as the proportion of samples with the target condi- 
ion (cCD) which tested positive using the index test. Its specificity 
as calculated as the proportion of samples without cCD, which 
ested negative using the index test. Missing data on the index or 
eference tests precluded analysis of the case. In this study, qPCR 
ositive results were not used for taking clinical decisions. 4 .10. Estimation of parasitic loads 
The kit was designed for qualitative amplification of T. cruzi 
NA. However, parasitic loads were quantified to further char- 
cterize those qPCR positive samples. Thus, a standard quantita- 
ive curve was constructed as follows: a pellet of epimastigotes 
CL-Brener stock) quantitated using a Neubauer chamber was sus- 
ended in EDTA-Blood and mixed with DNAgard to a final con- 
entration of 10 5 parasites/mL. DNA extraction was performed as 
escribed above and diluted serially (1/10) in DNA matrix negative 
or T. cruzi, which was extracted from a seronegative PVB sample 
ixed with DNAgard. Quantification curves ranged from 10,0 0 0 to 
 ·5 par.eq/mL and were amplified in each plate together with sam- 
les and controls. The qPCR conditions were the same as those for 
linical samples and the parasitic loads were automatically calcu- 
ated by the thermocycler software and expressed in par.eq/mL. 
.11. Identification of T. cruzi DTU groups 
The qPCR positive samples with parasitic loads higher than 5 
ar.eq/mL were genotyped using two different genotyping algo- 
ithms: 1) a Multiplex TaqMan Real Time qPCR algorithm for dis- 
inction of the six DTUs [16] , and 2) Hemi-nested PCRs targeting 
he spliced Leader-Intergenic Regions I and II to identify T. cruzi I 
350bp) and T. cruzi II/V/VI (300bp) groups, respectively [17] . The 
atter strategy has higher sensitivity than qPCR but cannot distin- 
uish among individual T. cruzi II, T. cruzi V or T. cruzi VI genotypes 
17] . 
.12. Statistical Analysis 
For data analysis we used the STATA software, version 11 and 
pidat software, version 3.1. A descriptive analysis was done over 
ll included cases. Absolute and relative frequencies of variables 
oncerning characteristics of mothers, pregnancy and delivery of 
he index case were calculated. For proportions, 95% confidence in- 
ervals (CI) were obtained. The same analysis was performed in 
omplete followed-up cases with final diagnosis. Comparison of 
roportions between cCD and not-cCD cases was performed using 
hi2 or Fischer exact tests, and comparison of means was done 
sing Student’s or Wilcoxon rank-sum tests, as appropriate. For 
nalysis of qPCR accuracy, receiver operating characteristic (ROC) 
urves and the corresponding areas under the curves (AUC) were 
arried out. A statistical comparison of the areas under two ROC 
urves derived from the same set of patients‘ samples was done 
y taking in account the correlation between the areas that is in- 
uced by the paired nature of the data, according to Hanley and 
c Neil [18] using a non-parametric approach [19] . A statistically 
ignificant level of p < 0 ·05 was assumed. Non-significant p values 
ere expressed as p:ns. 
.13. Role of the funding source 
The study sponsors did not have any role in study design, col- 
ection, analysis, and interpretation of data, writing of the report 
nd in the decision to submit the paper for publication. 
. Results 
.1. Participants and samples 
Out of 622 screened seropositive pregnant women, 559 were 
nrolled ( Fig. 1 ). Study cases were classified into two groups ac- 
ording to the period during which the first sample was collected. 
roup 1 clustered cases from which the first sample was obtained 
efore the neonate abandoned the maternity service (within the 
A.F. Benatar, E. Danesi, S.A. Besuschio et al. EBioMedicine 69 (2021) 103450 
Fig. 1. Flowchart of Prospective Field study to evaluate qPCR kit prototype for diagnosis of cCD. PVB: Peripheral Venous Blood; UCB: Umbilical Cord Blood; MM: MicroMethod. 















































rst 72 hours of age) and Group 2 included cases which first sam- 
le was collected when the outpatient had his first control be- 
ween four days and 22 weeks after birth. 
In Group 1, 256 mother-newborn binomials were enrolled. In 
5 newborns, UCB samples were obtained and PVB in 161. Out of 
hem, 85 cases had a second PVB collected between two and 28 
eeks and 147 completed follow-up around 10 months of age (68 
ith an UCB and 79 with a PVB first sample) ( Fig. 1 ). 
In Group 2, 303 binomials were enrolled. The first PVB sample 
as obtained from 259 neonates at a median age of 33 days (min 
our days, max 22 weeks). The remaining cases were not included 
ecause 44 women who had given their informed consent did not 
eturn to the corresponding HC (14 ·52% loss to follow-up); 223/259 
ested infants were followed-up at around 10 months of age for 
erodiagnosis. 
In sum, 370 cases were considered as complete followed-up 
ases ( Fig. 1 ). The number and type of samples from them are
etailed in Supplementary Table 1. Out of 370 infants with com- 
lete follow-up, 132 were born to CD mothers residing in an ur- 
an non-endemic area (Buenos Aires city and surroundings), 75 
n Tucumán, 56 in Chaco and 107 in Santiago del Estero endemic 
rovinces. Fourteen infants (3 ·78%) were diagnosed as cCD based 
n the gold-standard diagnostic algorithm. The rates of congenital 
ransmission, the number of UCB and PVB samples and the num- 
er of complete followed-up cases distributed per HC are shown in 
able 1 . w
o
b
5 .2. Diagnostic accuracy of qPCR 
The qPCR assay was carried out in 421 samples from 370 ba- 
ies. Out of them, 350 (57 UCB and 293 PVB) were included for 
nalysis of qPCR accuracy ( Table 2 and Supplementary Table 2). 
he remaining cases were excluded because their samples were 
ot valid at pre-analytical or analytical stages, as mentioned in 
ethods. The proportion of not valid samples was similar between 
CB (3/67; 4 ·47%) and PVB samples (26/349; 7 ·44%) (p:ns). Ex- 
luded qPCR results due to outlier values of IAC or to discordance 
etween duplicates was also similar between UCB and PVB valid 
amples (5/64 (7 ·8%) and 29/323 (8 ·9%), respectively (p: ns, Sup- 
lementary Table 2). The qPCR accuracy was estimated taking in 
ccount the source of the sample (UCB or PVB) and the moment 
t which it was withdrawn (before or after leaving the Maternity 
ervice, around 72 hs after birth) ( Table 2 ). The highest level of 
PCR accuracy (72 ·73% of sensitivity and 99 ·15% of specificity) was 
chieved in 246 PVB samples obtained between four and 133 days 
f life (median: 34 ·5 days), whereas qPCR in UCB samples (N = 57) 
ad 66 ·67% of sensitivity and 96 ·3% of specificity ( Table 2 ). The
UC of ROC analysis for qPCR was 0 ·8594 and 0 ·8148 for PVB and
CB samples, respectively while the AUC for MM was 0 ·6818 and 
 ·6 6 67 ( Fig. 2 ). No significant differences were observed between
he AUCs of ROC curves for paired MM and qPCR data obtained in 
VB and UCB samples (p = 0 ·08). 
Forty six neonates were tested in two consecutive samples, one 
ithdrawn at birth and the other one between four to 133 days 
f life ( Table 2 ). Two were MM negative cCD patients diagnosed 
y serology at 10 months of age. The qPCR was positive in both, in 
A.F. Benatar, E. Danesi, S.A. Besuschio et al. EBioMedicine 69 (2021) 103450 
Fig. 2. Analysis of ROC curves to compare the accuracy of qPCR (right panels) and MicroMethod (left panels) for diagnosis of cCD in UCB (a) and PVB (b) samples in infants 























































ne of them (4045, Table 3 ) from the UCB sample (1,418 par.eq/mL) 
nd from the PVB collected at 54 days of life (23,709 par.eq/mL). 
n the other one (4055, Table 3 ) qPCR was positive in the PVB ob-
ained 41 days after birth (54 par.eq/mL) but not in the UCB sam- 
le. 
Five qPCR positive samples from cCD were MM negative. Their 
iagnosis was assessed by serological analysis, except in case 1039 
hich presented discordant serological findings and was diagnosed 
ased on a positive MM performed at three months of age in a 
ample not available for qPCR analysis ( Table 3 ). Four cCD cases 
ad false negative qPCR results in PVB. Out of them, two cases 
ere also MM negative (1001 and 1006) and two MM positive 
2047 and 6004). Other five cCD cases had MM negative and qPCR 
ositive results:1039 (78 ·8 par.eq/mL), 1083 (356 par.eq/mL), 4045 
1418 par.eq/mL at birth and 23,709 par.eq/mL at 54 days of age), 
055 (53 ·4 par.eq/mL) and 4057 (82 par.eq/mL) ( Table 3 ). Besides, 
ase 4058 was diagnosed by means of MM positivity in UCB, 
n agreement with the qPCR-based result. Based on the MM re- 
ult, this cCD patient received trypanocidal treatment and during 
ollow-up, the PVB sample was negative by MM and qPCR, sug- 
esting parasitological response to treatment. 
.3. Genotyping of T. cruzi discrete typing units from cCD patients 
After decoding samples and identifying those belonging to cCD 
atients, T. cruzi DTUs were identified directly from the qPCR pos- 
tive DNA extracts ( Fig. 3 ). The multiplex qPCR algorithm allowed 
dentification of Tc V in five patients (Supplementary Figure 1) and 
L-IR I-II PCRs allowed identification of Tc II/V/VI group in six ad- 
itional cCD cases that were non-detectable by qPCR genotyping 
 Fig. 3 ). Samples from cCD 1001 and 2047 cases were qPCR nega-
ive at their first visit but qPCR positive at 10 months of age (la-6 eled §, Table 3 ) and so, DTU typing was carried out from the lat-
er ones. A qPCR positive UCB sample from the non-cCD case 4047 
howed a mixture of Tc I and Tc II/V/VI ( Fig. 3 a and b, 4047). Dis-
rete typing units Tc III or Tc IV were not detected. 
.4. External Quality assurance (EQC) of qPCR performance 
Qualitative PCR results were informed by the three participant 
aboratories. All laboratory units informed as non-detectable qPCR 
ll negative P101 control samples and as qPCR positive all sam- 
les spiked with T. cruzi parasites in the range between 1 ·5 and 
50 par.eq/mL (P102, P103 and P104 samples). Supplementary Ta- 
le 3 shows the descriptive statistics of the study. A Kappa coeffi- 
ient = 1 was obtained among the results reported by each labo- 
atory, indicating perfect agreement. In this data set, 99% of values 
ave a Z-score between -3 and 3, which means that values lied 
ithin three standard deviations. Supplementary Table 3b shows 
hat all the EQC results obtained by the participating laboratories 
ropped within the accepted limits. 
. Discussion 
The 63 d World Health Assembly (2010) advised governments 
o launch systems of early detection, in particular for diagnosis of 
ew infections and congenital infections in newborns. It was esti- 
ated that all new cases of cCD represented 22% (8,668/38,593) 
f the new cases of CD [20] . A report of CD in Argentina at
hat time estimated between 20 0,0 0 0 and 376,0 0 0 seropositive 
omen giving birth to between 23,0 0 0 and 43,0 0 0 children, out 
f whom between 1,140 to 2,145 would be infected [ 21 , 22 ]. In
016, the Panamerican Health Organization (PAHO) incorporated 
CD in the framework for elimination of mother-to-child transmis- 
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Fig. 3. Genotyping of Discrete typing Units in qPCR positive samples from cCD pa- 
tients. a. 1 • 5% Agarose gel electrophoresis showing identification of Tc II/V/VI sam- 
ples using SL-IR II Heminested PCR. PCR positive samples 1001 and 2047 were ob- 
tained from the corresponding infants at ten months of age. b. 1 • 5% Agarose gel 
electrophoresis showing identification of Tc I samples using SL-IR I Heminested PCR. 
The arrows indicate the specific amplicon. SCN: Seronegative blood sample; NTC: 
Non Template control; Tc I control: Silvio X-10 stock; Tc V control: MNCl2 stock; 
Mk 1 kb + , 1 kilobase plus DNA ladder molecular weight marker. Numbers above 
wells in red font indicate UCB samples, numbers in green font indicate PVB with- 
drawn at first follow-up time point and numbers in blue font indicate PVB collected 
























































































ion (EMTCT Plus) to boost control of vertical infections in the re- 
ion, together with HIV, Syphilis and Hepatitis B [23] . 
Home-brewed conventional PCR and qPCR based studies have 
ncouraged the use of molecular diagnostics for early detection 
f cCD [ 4 , 10 ]. Once the method is standardized and personnel
s trained, molecular methods exhibit high sensitivity and speci- 
city and the possibility of being monitored through the imple- 
entation of internal and external quality controls [24] . In the last 
ears, T. cruzi qPCR tests became commercially available in Europe 
8] . However, no evaluations have been made in the context of 
rospective field studies, precluding assess their accuracy in both 
ndemic and non-endemic scenarios. 
In the present study, the offspring of CD women resident in 
ocalities of high endemicity of Northern Argentina (HC2 to HC5, 
able 1 ) as well as of women living in Buenos Aires city, not en-
emic for CD (HC1, Table 1 ), were tested following STARD guide- 
ines. The overall rate of cCD was 3 ·78% (14/370 cases), similar 
o what was estimated in other studies in Argentina [ 30 , 31 ]. The
ighest percentage of cCD children was detected in the province 
f Chaco (HC3, 7 ·1%) followed by those detected in Buenos Aires 
HC1, 5 ·3%). Current parasitological assays require laboratory con- 
itions that are difficult to fulfill in general laboratories, such as 
imely observation of the sample and availability of skilled person- 
el [ 25 , 26 , 27 ]. Moreover, quality controls for parasitological obser- 
ation are not currently carried out in health centers. The MM has 
 detection limit of around 50 parasites/mL. In contrast, the qPCR 
ssay herein performed in samples from newborns/neonates, with 7 n analytical sensitivity below 1 parasite/mL 10 , would early detect 
 proportion of MM negative cases, allowing their prompt treat- 
ent and reducing their loss to follow-up after nine months of life, 
hen infants should be tested using serological methods [ 4 , 28 , 29 ].
egarding serological methods for cCD diagnosis, the possibility of 
mmune tolerance to parasite antigens in cCD might explain some 
alse-negative serological results observed in infected infants. On 
he other hand, the transmission of maternal antibodies to new- 
orns which results in false-positive serological diagnosis can be 
vercome using molecular tools. Indeed, qPCR positive findings are 
ndicative of the presence of the parasite in the tested sample in- 
ependently of the host‘s immune status. 
In the present study, the rate of early diagnosis determined by 
M was 1 ·89% (7/370 cCD cases), whereas qPCR detected 2 ·70% 
10/370 cases), out of which five were also MM positive. The five 
emaining cases were MM negative, so these infants were diag- 
osed as cCD only at ten months of age. On the other hand, two 
atients, whose samples were collected at one (6004) and 11 days 
2047) of age, were MM positive but qPCR negative. This finding 
as not expected, given the high analytical sensitivity of the qPCR. 
nhibition of qPCR was not observed in these samples as indicated 
y correct IAC amplification, and the sample collected from case 
047 at ten months of age was qPCR positive and could be geno- 
yped ( Table 3 and Fig. 3 ). Technical problems such as DNA degra-
ation during collection, storage and/or transportation of the blood 
ample from the endemic locality to the qPCR laboratory might 
ave been possible causes for these false negative qPCR findings. 
Four non-infected cases gave false positive qPCR findings, two 
n UCB (4047: 39 par.eq/mL and 5069: 0 ·45 par.eq/mL, Table 3 ). 
ample from case 4047 was genotyped and gave a mixed TcI plus 
cII/V/VI population, indicating not only the presence of satel- 
ite DNA but also of spliced-leader intergenic nuclear sequences 
 Table 3 and Fig. 3 ). A parasitic load of 39 par.eq/mL seems 
oo high to be a false positive result due to laboratory cross- 
ontamination with another infected sample. Besides, amplicon 
arry-over contamination is unlikely because the kit incorporates 
n Uracil DNA Glycosylase system. Thus, it might be speculated 
hat this UCB sample could contain maternal parasite traces de- 
pite the care and umbilical cord decontamination step done dur- 
ng collection of the sample (see Methods). Otherwise, sponta- 
eous cure, which is the clearance of the infection without the 
eed of treatment, could be a plausible explanation for this ob- 
ervation, as previously reported [32–34] . The other two false 
ositive samples were processed simultaneously to true positive 
nes: PVB 4044 (3 ·64 par.eq/mL) was processed together with 
CD 4045 (23,709 par.eq/mL) and PVB 1110 (0 ·44 par.eq/mL) was 
rocessed together with cCD 1111 (641 par.eq/mL).The high par- 
sitic loads of the above-mentioned samples suggest that cross- 
ontamination during sample collection, transportation and/or DNA 
xtraction might have occurred ( Table 3 ). Indeed, samples col- 
ected in HC4 exhibited a higher proportion of inconclusive results 
13 ·33%, Table 1 ) because of discordant qPCR duplicates, which in 
art could have arisen by cross-contamination between consecu- 
ive samples. 
Maximum qPCR accuracy (sensitivity 72 ·73%, specificity 91 ·9%) 
as obtained in PVB collected around one month of age (34 ·5 
ays). It has been reported that a proportion of samples collected 
rom cCD patients close to delivery may present low parasitic 
oads. Indeed, cCD case 4045 showed higher parasitic loads in the 
VB collected at day 54 than in the UCB sample, and case 4055 
as qPCR positive at 41 days of age and negative in the UCB sam- 
le ( Table 3 ). ROC curve analysis suggested higher accuracy for 
PCR in PVB than in UCB samples, although the difference did 
ot reach significance levels (p = 0 ·08). Previous studies observed 
hat diagnosis has higher sensitivity around the first month of 
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Fig. 4. Proposed algorithm for diagnosis of cCD. Detectable MM and/or qPCR findings of a neonate ́s PVB-based DNA lysate are reported as cCD. P: Positive, N: Negative, ∗If 








































































ge and at that time, the likelihood of false positive results de- 
ived from passage of maternal T. cruzi DNA to the newborn is dis- 
arded [ 4 , 5 , 34 , 35 ]. The study designed as criterion of qPCR posi-
ivity or negativity the concordance of results between duplicates, 
hich led to the detection to 7 ·8% and 8 ·9% of discordant findings
n UCB and PVB, respectively. To diminish the proportion of dis- 
ordant results, additional analyses were performed. The first one 
onsidered as qPCR positive a sample with at least one qPCR repli- 
ate detectable at Cq < 39. In PVB samples, this criterion allowed 
 higher qPCR sensitivity (76 ·92%) but lower specificity (92 ·83%) 
nd in UCB, sensitivity was 66 ·67% and specificity only 88 ·14%. 
ndeed, this criterion gave rise to 18 false positive qPCR results 
mong 264 tested PVB and 7 false positive qPCR results among 62 
ested UCB samples. To obtain higher qPCR accuracy when testing 
nly one replicate, the maximum Cq value for qPCR positivity was 
owered below 37. In this case, sensitivity was 72 ·73% and speci- 
city 98 ·31% for PVB and 66 ·67% and 96 ·30% for UCB, respectively
 Table 4 ). These findings allowed us to propose an algorithm for 
eliable diagnosis of cCD, employing qPCR and MM at delivery and 
round one month of life in PVB samples ( Fig. 4 ). A Cq < 37 in at
east one replicate determines a qPCR positive result. If the Cq is 
 37 and < 39 in only one replicate, the result should be consid-
red inconclusive and therefore DNA extraction and qPCR ampli- 
cation should be repeated. Finally, a Cq > 39 is interpreted as a 
on-detectable qPCR result ( Fig. 4 ). 
Establishment of EQC assurance [37] is relevant for accompa- 
ying PCR-based field studies for monitoring the quality of the 
PCR procedures carried out. Accordingly, EQC was implemented 
n three different laboratories that used different thermocyclers 
nd were operated by different technicians. Statistical analysis 
howed concordant qualitative qPCR results (Kappa coefficient = 1). 
oreover, all samples spiked with 1 ·5 to 150 par.eq/mL, as well 
s the positive DNA controls provided by the kit gave amplifi- 
ation signals, whereas non-spiked seronegative blood gave non- 
etectable qPCR findings, demonstrating the high inter-laboratory 
eproducibility of the assay. 
Genotyping allowed detection of Tc V in those cCD samples har- 
oring 641-23,709 par.eq/mL. Samples with lower parasitic loads 8 ould be only genotyped by means of conventional SL-IR based 
eminested PCRs, resulting in Tc II/V/VI. Indeed, the latter strategy 
s more sensitive than qPCR, although it cannot provide a distinc- 
ion among TcII, TcV and TcVI DTUs [ 16 , 17 ]. The predominance of
c V in cCD has been reported in the southern cone [36] , in agree-
ent with its predominance in the general population, suggesting 
o associations between certain DTUs and cCD [ 1 , 17 , 38 ]. The only
ample exhibiting Tc I plus Tc II/V/VI mixed populations was an 
CB from a non-infected newborn. It is tempting to speculate that 
c I strains circulate in bloodstream at lower parasitic loads and 
ccordingly are more difficult to be detected. A recent case report 
f a cCD child who tested negative by microscopic observation and 
CR done at 20 days and 6 months of age, identified a Tc I isolate
btained by hemoculture at seven months of age [39] . 
We did not find clinical and sociodemographic characteristics 
ssociated to the likelihood of cCD transmission, except for a 
igher frequency of previously infected brothers and sisters of the 
CD cases confirming previous evidence of family clustering of cCD 
3] . Previous works suggested an association between infants’ par- 
sitic loads and the severity of clinical manifestations in cCD 26Ç
26,27] . In our cohort, two cases (1044 and 4045, Table 3 ) depicted
igh parasitic loads. The former case was born at week 36th (2 ·5 
gr) without any complication except hospitalization due to bron- 
hiolitis and the latter was born at week 36th (2 ·78 kgr) without 
omplications except one admission to hospital at one month of 
ge due to an ovarian surgery not related to cCD. 
Previous international qPCR validation studies were done in 
dult blood samples and hence PCR clinical sensitivity was esti- 
ated from 10 or 5 mL of blood treated with equal volumes of 
uanidinium Hidrochloride 6M, EDTA 0.2 M, pH 8 ·00 (GE) as sta- 
ilizing agent, volume that is feasible to obtain from UCB but prob- 
ematic to collect from neonates ́PVB [ 10 , 40 ]. The present study em-
loyed only 1 ·2 mL of neonatal blood plus 0 ·3 mL of a commer-
ial stabilizer. The combination of DNA extraction and amplifica- 
ion steps allows results in just over three hours, in a straightfor- 
ard way with standardized reagents and quality controls. 
Nevertheless, the commercial stabilizer herein used resulted not 
ptimal for blood storage. Many samples became viscous and diffi- 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































9 ult to manipulate, so they could not be processed (not valid sam- 
les, Table 1 ). It is expected that further prospective studies using 
DTA or GE blood [ 41 , 42 ] will improve the kit performance. 
During the study, 189 babies (33 ·8%) could not be followed-up. 
his occurred particularly in the three endemic sites with higher 
redominance of rural populations ( Table 1 , HC3, 4 and 5), while 
C2 is located in an endemic area with certification of vector- 
orne transmission control. Two cases from HC4, without complete 
ollow-up (unpublished results), had positive qPCR findings with 
igh parasitic loads, which suggested cCD. Therefore, these cases 
ere reported to the site for diagnosis confirmation and treatment. 
National guidelines have mentioned qPCR as a potential labo- 
atory tool for early cCD diagnosis. However, no field prospective 
orks had been performed so far [ 6 , 29 ]. Also, current guidelines
o not consider performing tests around one month of age, which 
e found optimal for qPCR and parasitological studies, and ac- 
ordingly we have included it in the proposed algorithm. Conse- 
uently, this study may contribute to implement qPCR for IVD use, 
iming to improve current early diagnosis of cCD in those coun- 
ries that only perform parasitological methods. The sensitivity of 
his qPCR kit was almost twice than that of the MM. Messenger 
nd coworkers [5] detected 68 ·6% versus 16 ·7% of sensitivity in 
CB for qPCR and MM, respectively, reaching a cumulative sensi- 
ivity of 84 ·2% and 34 ·2% when a second analysis was performed 
n the same patients at one month of age. 
Future evaluation of the qPCR kit performance in molecular bi- 
logy laboratories located at endemic areas using EDTA or GE- 
reated samples, would reduce the problems related to sample 
ransportation observed in this study. Its use, in combination with 
he MM, should improve early detection of cases and provide more 
ccurate records on the number of cCD infants in endemic and 
on-endemic countries. Such data would be useful in estimating 
he likely number of cases missed in places where only traditional 
arasitological procedures are still employed. [43] Moreover, incor- 
oration of standard curves for quantification of parasitic loads 
ay provide a useful tool to monitoring patients under treatment 
nd to study associations between parasitic burden and cCD clin- 
cal severity. Indeed, qPCR-based early diagnosis will contribute to 
aximize prompt treatment to infected neonates with high impact 
n public health [ 22 , 42 , 43 ]. 
escription of this data 
The file FITS SALUD CHAGAS 001 Study_public data base.cvs 
ontains all the variables used in the analysis of the manuscript 
Multicenter Field Evaluation of Real time PCR Kit prototype for 
arly Diagnosis of Congenital Chagas disease”. The data set is struc- 
ured with one record per each screened T. cruzi infected mother- 
ewborn binomial. Each of the 622 screened binomials was as- 
igned with an ID, which is the first variable included in the data 
et, and subsequently variables on binomials’ characteristics of in- 
erest and laboratory results for the 559 recruited binomials have 
een incorporated. Variables were obtained from: i) study forms 
o collect information from clinical records or participants´answers, 
i) specific data forms for laboratory results, and iii) from previous 
ariables. In the file FonarsecStudy_DataDictionary.doc is detailed 
he information for each variable. 
The analysis of this data set was done with Stata version 11.2, 
nd some complementary analysis was performed using EpiDat 
ersion 3.1. 
ontributors 
AGS, SSE and FR designed the trial with input from JB, ME, MLC 
nd FA. Trial coordination, management and clinical data collec- 
ion was performed by SAB, ED, SL and MLC with the input of 
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Table 2 
Positivity by MicroMethod and qPCR in valid samples obtained from complete followed-up cases 
Sample Type (cCD / tested samples) Diagnostic accuracy study MicroMethod (positive/ tested samples) ∗ qPCR (positive/ tested samples) ∗
UCB a (3/57) (1/57) (2/57) 
Sensitivity % (95% CI) 33.33 (0.00-100.00) 66.67 (0.00-100.00) 
Specificity % (95% CI) 100.00 (99.07-100.00) 96.30 (90.33-100.00) 
PPV % (95% CI) 50.00 (50.00-100.00) 50.00 (50.00-100.00) 
NPV % (95% CI) 96.43 (90.68-100.00) 98.11 (93.51-100.00) 
PVB b (11/246) (4/246) (8/246) 
Sensitivity % (95% CI) 36.36 (3.39-64.34) 72.73 (41.86-100.00) 
Specificity % (95% CI) 100.00 (99.79-100.00) 99.15 (97.76-100.00) 
PPV % (95% CI) 97.11 (94.79-100.00) 80.00 (50.21-100.00) 
NPV % (95% CI) 97.18 (94.91-99.44) 98.73 (97.09-100.00) 
All samples c (14/350) (6/350) (10/350) 
Sensitivity % (95% CI) 40.00 (11.87-68.13) 66.67 (39.48-93.86) 
Specificity % (95% CI) 100.00 (99.85-100.00) 98.81 (97.49-100.00) 
PPV % (95% CI) 100.00 (91.67-100.00) 71.43 (44.19-98.66) 
NPV % (95% CI) 97.38 (95.55-99.22) 98.51 (97.11-99.96) 
UCB or PVB d (2/46) (0/46) (2/46) 
Sensitivity % (95% CI) 100.00 (75.00-100.00) 
Specificity % (95% CI) 97.73 (92.19-100.00) 
PPV % (95% CI) 66.67 (0.00-100.00) 
NPV % (95% CI) 100.00 (98.84-100.00) 
cCD: Congenital Chagas Disease; a- UCB: Umbilical Cord Blood collected at birth; b- PVB: Peripheral Venous Blood collected after 72 hours, till five 
months of life (day 4-133); c- UCB and PVB collected from day 0-133; d- Cases with two blood samples, one collected at birth and the other one in 
the second visit. 
∗Numbers in bold between parentheses indicate the rate of positive results out of the tested samples using the MicroMethod or qPCR. CI: Confidence 
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a: MicroMethod, qPCR, serological and Discrete Typing Unit results in congenital Chagas Disease patients. 
ID Site Umbilical Cord blood Peripheral Venous Blood Serodiagnosis at 10 months Discrete Typing Units 
MM qPCR Par Load MM qPCR Par Load Age (days) Diagnosis ELISA HAI IFI SL IR II SL-IR I TaqMan PCR 
1001 HC1 NA NA x Neg Neg x 64 Reactive 0 ·759 Ɛ 64 ¤ 32 ø Tc II/V/VI§ Neg Neg 
1006 HC1 NA NA x Neg Neg x 118 Reactive 4 ·442§ 256 ¤ ND ND ND ND 
1039 HC1 NA NA x Neg Pos 78 ·8 33 Discordant ∗♦ 0 ·015 ß 128 ¤ NR Tc II/V/VI Neg Neg 
1044 HC1 NA NA x Pos Pos 3684 87 Non Reactive ∗ 0 ·015 ß NR ¤ ND Tc II/V/VI Neg Tc V 
1083 HC1 NA NA x Neg Pos 356 36 Reactive 2 ·985 ß 256 ¤ ND Tc II/V/VI Neg Neg 
1111 HC1 NA NA x Pos Pos 641 10 Non Reactive ∗ 0 ·036 ¥ NR ¤ ND Tc II/V/VI Neg Tc V 
1167 HC1 NA NA x Pos Pos 37 ·5 49 Reactive 2 ·501 ß 256 ¤ ND Tc II/V/VI Neg Neg 
2037 HC2 NA NA x Pos Pos 0 9 Non Reactive ∗ 0 ·018 § NR ¤ ND ND ND ND 
2047 HC2 NA NA x Pos Neg x 11 Reactive 2 ·624 § 256 ¤ ND Tc II/V/VI§ Neg Tc V 
4045 HC3 Neg Pos 1418 Neg Pos 23709 54 Reactive 2 ·624 ¥ 256 ¤ ND Tc II/V/VI Neg Tc V 
4055 HC3 Neg Neg x Neg Pos 53 ·4 41 Reactive 2 ·531 ß 128 ¤ ND Tc II/V/VI Neg Neg 
4057 HC3 NA NA x Neg Pos 82 ·0 45 Reactive 1 ·418 ¥ 256 ¤ ND Tc II/V/VI Neg Neg 
4058 HC3 Pos Pos 1370 Neg Neg x NA Non Reactive ∗ 0 ·059 ¥ NR ¤ ND Tc II/V/VI Neg Tc V 
6004 HC4 NA NA x Pos Neg x 1 Non Reactive ∗ 0 ·017 § NR ¤ ND ND ND ND 
b: MicroMethod, qPCR, serological and Discrete Typing Unit results in non congenital Chagas Disease patients. 
1110 HC1 NA NA x Neg Pos 0 ·44 12 Non Reactive NR NR ¤ ND ND ND ND 
4044 HC3 NA NA x Neg Pos 3 ·64 69 Non Reactive NR NR ¤ ND ND ND ND 
4047 HC3 Neg Pos 39 NA NA x x Non Reactive NR NR ¤ ND Tc II/V/VI Tc I Neg 
5069 HC5 Neg Pos 0 ·45 NA NA x x Non Reactive NR NR ¤ ND ND ND ND 
MM: MicroMethod; Par load: Parasitic load in par.eq/mL ∗ Treated patient: NA: Not available sample; ND: Not done; Pos: Positive; Neg: Negative; x: Not tested/No data; NR: Non 
Reactive 
Ɛ cut-off: 0 ·152; § cut-off: 0 ·318; ß cut-off: 0 ·316; ¥ cut-off: 0 ·322; ¤ cut-off: dilution factor 16; ø cut-off: dilution factor 32; ♦ Case diagnosed by a positive MM on a second 
routine control at 3 months of age and treated. § DTUs were identified in qPCR positive samples obtained at ten month of age. 
Table 4 
Operational parameters of the qPCR assay in complete followed-up infants, using as criteria of positivity Cq values in one or both DNA replicates. 
Sample Type Rate of cCD by Gold Standard qPCR results Rate of detection by qPCR Sensitivity Specificity PPV NPV 
% (95% CI) % (95% CI) % (95% CI) % (95% CI) 
UCB 3/57 1 rep · Cq < 37 2/57 66 ·67 (0 ·00-100 ·00) 96 ·30 (90 ·33-100 ·00) 50 ·00 (50 ·00-100 ·00) 98 ·11 (93 ·51-100 ·00) 
3/62 1 rep · Cq < 39 2/62 66 ·67 (0 ·00-100 ·00) 88 ·14 (79 ·04-97 ·23) 22 ·22 (0 ·00-54 ·94) 98 ·11 (93 ·51-100 ·00) 
3/57 2 rep · Cq < 39 2/57 66 ·67 (0 ·00-100 ·00) 96 ·30 (90 ·33-100 ·00) 50 ·00 (50 ·00-100 ·00) 98 ·11 (93 ·51-100 ·00) 
PVB 11/248 1 rep · Cq < 37 8/248 72 ·73 (41 ·86-100 ·00) 98 ·31 (96 ·46-100 ·00) 66 ·67 (35 ·83-97 ·51) 98 ·73 (97 ·09-100 ·00) 
13/264 1 rep · Cq < 39 10/264 76 ·92 (50 ·17-100 ·00) 92 ·83 (89 ·44-96 ·22) 35 ·71 (16 ·18-55 ·25) 98 ·73 (97 ·09-100 ·00) 
11/246 2 rep · Cq < 39 8/246 72 ·73 (41 ·86-100 ·00) 99 ·15 (97 ·76-100 ·00) 80 ·00 (50 ·21-100 ·00) 98 ·73 (97 ·09-100 ·00) 
UCB: Umbilical Cord Blood; PVB: Peripheral Venous Blood; Rep: replicate; Ct: threshold cycle; CI: confidence interval; PPV: Positive Predictive Value; NPV: Negative Predictive Value. 
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